Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06555237 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies

Study acronym: MEKinRAS
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 15, 2024 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
The goal of this study is to evaluate the effectiveness of trametinib treatment in patients with Hyperthropic cardiomyopathy and a genetic mutation in the RAS/MAPK pathway.
Trial Details
NCT Number NCT06555237
Lead Sponsor Medical University of Warsaw
Conditions
(from sponsor)		 Cardiomegaly, Noonan Syndrome
Related terms Cardiomegaly, Cardiomyopathies, Noonan Syndrome
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov